Genetic risk factors start to affect the brain and behavior in Alzheimer's disease (AD) before clinical symptoms occur. Although AD is mainly associated with memory deficits, attention and executive dysfunctions can present at the early presymptomatic stages in middle age for those with non-modifiable risks.
Objective
Here, we investigated whether known risk genes for AD already affected attention in young adulthood.
Methods
A total of 392 healthy young adults aged around 20 years underwent genetic testing for risks of dementia (APOE and MAPT) and performed a computerized cognitive test for temporal attention called the Attentional Blink (AB) task, in which patients with dementia tested in previous studies often showed reduced performance. Here, the AB task was analyzed using repeated-measurements analysis of variance for the ability of visual perception, attention deployment and temporal memory encoding/binding performance.
Results
The results showed that all participants exhibited AB effects. Importantly, genetic risk factors had statistically significant influence on temporal attention depending on sex in healthy young adults. APOE4 status was associated with enhanced attention deployment in males but not females, while MAPT AA carriers had poorer performance in AB but only in females. No genetic effects were found for visual perception and temporal memory binding errors between high and low risk groups.
Conclusions
We provided evidence that both APOE and MAPT start to affect attentional function as early as young adulthood. Furthermore, unlike previous findings in older people, these genes had a differential effect for males and females in young adults.
RustedJMEvansSLKingSL, et al.APOE E4 polymorphism in young adults is associated with improved attention and indexed by distinct neural signatures. Neuroimage2013; 65: 364–373.
5.
NewcombeEACamats-PernaJSilvaML, et al.Inflammation: the link between comorbidities, genetics, and Alzheimer's disease. J Neuroinflammation2018; 15: 276.
6.
SimsRHillMWilliamsJ. The multiplex model of the genetics of Alzheimer's disease. Nat Neurosci2020; 23: 311–322.
7.
TangXLiuSCaiJ, et al.Effects of gene and plasma tau on cognitive impairment in rural Chinese population. Curr Alzheimer Res2021; 18: 56–66.
8.
SilvaMVFLouresCMGAlvesLCV, et al.Alzheimer's disease: risk factors and potentially protective measures. J Biomed Sci2019; 26: 33.
9.
BertramLTanziRE. Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. Nat Rev Neurosci2008; 9: 768–778.
10.
GiriMZhangMLuY. Genes associated with Alzheimer's disease: an overview and current status. Clin Interv Aging2016; 11: 665–681.
11.
StevensBWDiBattistaAMRebeckGW, et al.A gene-brain-cognition pathway for the effect of an Alzheimer's risk gene on working memory in young adults. Neuropsychologia2014; 61: 143–149.
12.
JiangQLeeCYMandrekarS, et al.Apoe promotes the proteolytic degradation of Abeta. Neuron2008; 58: 681–693.
13.
El HajMAntoinePAmouyelP, et al.Apolipoprotein E (APOE) epsilon4 and episodic memory decline in Alzheimer's disease: a review. Ageing Res Rev2016; 27: 15–22.
14.
MedeirosRBaglietto-VargasDLaFerlaFM. The role of tau in Alzheimer's disease and related disorders. CNS Neurosci Ther2011; 17: 514–524.
15.
WiderCVilarino-GuellCJasinska-MygaB, et al.Association of the MAPT locus with Parkinson's disease. Eur J Neurol2010; 17: 483–486.
16.
MyersAJKaleemMMarloweL, et al.The H1c haplotype at the MAPT locus is associated with Alzheimer's disease. Hum Mol Genet2005; 14: 2399–2404.
17.
ZhouFWangD. The associations between the MAPT polymorphisms and Alzheimer's disease risk: a meta-analysis. Oncotarget2017; 8: 43506–43520.
18.
WendelkenLAJahanshadNRosenHJ, et al.Apoe epsilon4 is associated with cognition, brain integrity, and atrophy in HIV over age 60. J Acquir Immune Defic Syndr2016; 73: 426–432.
19.
BoylePABuchmanASWilsonRS, et al.The APOE epsilon4 allele is associated with incident mild cognitive impairment among community-dwelling older persons. Neuroepidemiology2010; 34: 43–49.
20.
StringaNvan SchoorNMMilaneschiY, et al.Physical activity as moderator of the association between APOE and cognitive decline in older adults: results from three longitudinal cohort studies. J Gerontol A Biol Sci Med Sci2020; 75: 1880–1886.
21.
MakkarSRLipnickiDMCrawfordJD, et al.APOE Epsilon4 and the influence of sex, age, vascular risk factors, and ethnicity on cognitive decline. J Gerontol A Biol Sci Med Sci2020; 75: 1863–1873.
22.
BretskyPGuralnikJMLaunerL, et al.The role of APOE-epsilon4 in longitudinal cognitive decline: macArthur studies of successful aging. Neurology2003; 60: 1077–1081.
23.
MondadoriCRde QuervainDJBuchmannA, et al.Better memory and neural efficiency in young apolipoprotein E epsilon4 carriers. Cereb Cortex2007; 17: 1934–1947.
24.
DowellNGRuestTEvansSL, et al.MRI Of carriers of the apolipoprotein E e4 allele-evidence for structural differences in normal-appearing brain tissue in e4+relative to e4- young adults. NMR Biomed2013; 26: 674–682.
25.
WierengaCEClarkLRDevSI, et al.Interaction of age and APOE genotype on cerebral blood flow at rest. J Alzheimers Dis2013; 34: 921–935.
26.
HanSDBondiMW. Revision of the apolipoprotein E compensatory mechanism recruitment hypothesis. Alzheimers Dement2008; 4: 251–254.
27.
IhleABunceDKliegelM. APOE Epsilon4 and cognitive function in early life: a meta-analysis. Neuropsychology2012; 26: 267–277.
28.
BunceDBielakAAAnsteyKJ, et al.APOE Genotype and cognitive change in young, middle-aged, and older adults living in the community. J Gerontol A Biol Sci Med Sci2014; 69: 379–386.
29.
ChenXFWeiZWangT, et al.Demographic and lifestyle characteristics, but not apolipoprotein E genotype, are associated with intelligence among young Chinese college students. PLoS One2015; 10: e0143157.
30.
WeissbergerGHNationDANguyenCP, et al.Meta-analysis of cognitive ability differences by apolipoprotein e genotype in young humans. Neurosci Biobehav Rev2018; 94: 49–58.
31.
GersteneckerARobersonEDSchellenbergGD, et al.Genetic influences on cognition in progressive supranuclear palsy. Mov Disord2017; 32: 1764–1771.
32.
Winder-RhodesSEHampshireARoweJB, et al.Association between MAPT haplotype and memory function in patients with Parkinson's disease and healthy aging individuals. Neurobiol Aging2015; 36: 1519–1528.
33.
MataIFLeverenzJBWeintraubD, et al.APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease. JAMA Neurol2014; 71: 1405–1412.
34.
PerryRJHodgesJR. Attention and executive deficits in Alzheimer's disease: a critical review. Brain1999; 122: 383–404.
35.
Prats-SedanoMASavulichGSurendranathanA, et al.The revised Addenbrooke's cognitive examination can facilitate differentiation of dementia with Lewy bodies from Alzheimer's disease. Int J Geriatr Psychiatry2021; 36: 831–838.
36.
MalhotraADhutiaHFinocchiaroG, et al.Outcomes of cardiac screening in adolescent soccer players. N Engl J Med2018; 379: 524–534.
37.
JackCRHoltzmanDM. Biomarker modeling of Alzheimer’s disease. Neuron2013; 80: 1347–1358.
38.
RitchieCWWellsKRitchieK. The PREVENT research programme–a novel research programme to identify and manage midlife risk for dementia: the conceptual framework. Int Rev Psychiatry2013; 25: 748–754.
39.
KucikovaLZengJMuñoz-NeiraC, et al.Genetic risk factors of Alzheimer’s disease disrupt resting-state functional connectivity in cognitively intact young individuals. J Neurol2023; 270: 4949–4958.
40.
HuangWZengJJiaL, et al.Genetic risks of Alzheimer’s by APOE and MAPT on cortical morphology in young healthy adults. Brain Commun2023; 5: fcad234.
41.
ShapiroKLRaymondJEArnellKM. The attentional blink. Trends Cogn Sci1997; 1: 291–296.
42.
VardyYBradshawJLIansekR. Dual target identification and the attentional blink in Parkinson's disease. J Clin Exp Neuropsychol2003; 25: 361–375.
43.
SuLWybleBZhouLQ, et al.Temporal perception deficits in schizophrenia: integration is the problem, not deployment of attentions. Sci Rep2015; 5: 9745–9745.
PetersFErgisA-MGauthierS, et al.Abnormal temporal dynamics of visual attention in Alzheimer's disease and in dementia with Lewy bodies. Neurobiol Aging2012; 33: 1012.e1–10.
46.
RustedJEvansSKingS, et al.APOE E4 polymorphism in young adults is associated with improved attention and indexed by distinct neural signatures. Neuroimage2013; 65: 364–373.
47.
VisserTAWBodenCGiaschiDE. Children with dyslexia: evidence for visual attention deficits in perception of rapid sequences of objects. Vision Res2004; 44: 2521–2535.
48.
RussoNKatesWRWybleB. Developmental changes in feature detection across time: evidence from the attentional blink. J Exp Child Psychol2017; 164: 32–44.
49.
Lorca-PulsDLGajardo-VidalAWhiteJ, et al.The impact of sample size on the reproducibility of voxel-based lesion-deficit mappings. Neuropsychologia2018; 115: 101–111.
50.
PotterHWisniewskiT. Apolipoprotein E: essential catalyst of the Alzheimer amyloid cascade. Int J Alzheimers Dis2012; 2012: 489428.
51.
PikeCJ. Sex and the development of Alzheimer's disease. J Neurosci Res2017; 95: 671–680.
52.
AltmannATianLHendersonVW, et al.Sex modifies the APOE-related risk of developing Alzheimer disease. Ann Neurol2014; 75: 563–573.
53.
NeuSCPaJKukullW, et al.Apolipoprotein E genotype and sex risk factors for Alzheimer disease: a meta-analysis. JAMA Neurol2017; 74: 1178–1189.
54.
TakeuchiHTomitaHBrowneR, et al.Sex-dependent effects of the APOE ɛ4 Allele on behavioral traits and white matter structures in young adults. Cereb Cortex2021; 31: 672–680.
55.
ZokaeiNGiehlKSillenceA, et al.Sex and APOE: a memory advantage in male APOE ε4 carriers in midlife. Cortex2017; 88: 98–105.
56.
NewtonCPopeMRuaC, et al.Entorhinal-based path integration selectively predicts midlife risk of Alzheimer's disease. Alzheimers Dement2024; 20: 2779–2793.
57.
BangasserDAEckSROrdoñes SanchezE. Sex differences in stress reactivity in arousal and attention systems. Neuropsychopharmacology2019; 44: 129–139.
58.
BowmanHWybleB. The simultaneous type, serial token model of temporal attention and working memory. Psychol Rev2007; 114: 38.
59.
CrastonPWybleBChennuS, et al.The attentional blink reveals serial working memory encoding: evidence from virtual and human event-related potentials. J Cogn Neurosci2009; 21: 550–566.
60.
WybleBBowmanHNieuwensteinM. The attentional blink provides episodic distinctiveness: sparing at a cost. J Exp Psychol Hum Percept Perform2009; 35: 787.
61.
WybleBPotterMCBowmanH, et al.Attentional episodes in visual perception. J Exp Psychol Gen2011; 140: 488.
62.
LaharCJIsaakMIMcArthurAD. Age differences in the magnitude of the attentional blink. Aging Neuropsychol Cogn2001; 8: 149–159.
63.
Georgiou-KaristianisNTangJVardyY, et al.Progressive age-related changes in the attentional blink paradigm. Aging Neuropsychol Cogn2007; 14: 213–226.
64.
Perez-ValeroEGutierrezCAMLopez-GordoMA, et al.Evaluating the feasibility of cognitive impairment detection in Alzheimer’s disease screening using a computerized visual dynamic test. J Neuroeng Rehabil2023; 20: 43.
65.
BarnardNDBushAICeccarelliA, et al.Dietary and lifestyle guidelines for the prevention of Alzheimer's disease. Neurobiol Aging2014; 35: S74–S78.
66.
BrookmeyerRJohnsonEZiegler-GrahamK, et al.Forecasting the global burden of Alzheimer’s disease. Alzheimers Dement2007; 3: 186–191.
